This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Vildagliptin is an antidiabetic agent belonging to the class of dipeptidyl peptidase-4 inhibitors, used for the treatment of type 2 diabetes mellitus. Its effects are based on the inhibition of the enzyme dipeptidyl peptidase-4, which is responsible for the degradation of endogenous incretins. The tablets are taken once or twice daily regardless of meals. The most common possible adverse effects include dizziness, tremor, and nausea. Vildagliptin does not interact with CYP450.
Vildagliptin (ATC A10BH02) has antidiabetic properties. Its effects are based on the selective inhibition of dipeptidyl peptidase-4 (DPP-4). Vildagliptin promotes insulin synthesis and release from the beta cells of the pancreas, improves the sensitivity of beta cells to glucose, and increases its uptake into tissues. It reduces glucagon secretion from the alpha cells, thereby leading to decreased hepatic glucose production.
Mechanism of action of gliptins, click to enlarge. Illustration © PharmaWiki
